Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-03
2007-04-03
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C546S114000, C514S301000, C544S127000
Reexamination Certificate
active
10666857
ABSTRACT:
Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
REFERENCES:
patent: 3845065 (1974-10-01), Shen et al.
patent: 3903095 (1975-09-01), Shen et al.
patent: 6022884 (2000-02-01), Mantlo et al.
patent: 6649654 (2003-11-01), Karin et al.
patent: WO 95/02597 (1995-01-01), None
patent: WO 01/00610 (2001-01-01), None
patent: WO 01/30774 (2001-03-01), None
patent: WO 01/28993 (2001-04-01), None
patent: WO 01/58890 (2001-08-01), None
patent: WO 01/58899 (2001-08-01), None
patent: WO 01/68648 (2001-09-01), None
patent: WO 02/28860 (2002-04-01), None
patent: WO 02/30353 (2002-04-01), None
patent: WO 02/30423 (2002-04-01), None
patent: WO 02/41843 (2002-05-01), None
patent: WO 02/44153 (2002-06-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 02/060386 (2002-08-01), None
patent: WO 02/076985 (2002-10-01), None
patent: WO 02/094265 (2002-11-01), None
patent: WO 02/094322 (2002-11-01), None
patent: WO 02/094813 (2002-11-01), None
patent: WO 03/010158 (2003-02-01), None
patent: WO 03/024935 (2003-03-01), None
patent: WO 03/024936 (2003-03-01), None
patent: WO 03/027075 (2003-04-01), None
patent: WO 03/029242 (2003-04-01), None
patent: WO 03/035625 (2003-05-01), None
patent: WO 03/037886 (2003-05-01), None
patent: WO 03/039545 (2003-05-01), None
patent: WO 03/040131 (2003-05-01), None
patent: WO 03/070706 (2003-08-01), None
patent: WO 03/086309 (2003-10-01), None
patent: WO 03/084959 (2003-11-01), None
patent: WO 03/095430 (2003-11-01), None
patent: WO 03/103648 (2003-12-01), None
patent: WO 03/103658 (2003-12-01), None
patent: WO 03/103661 (2003-12-01), None
patent: WO 03/104218 (2003-12-01), None
patent: WO 03/104219 (2003-12-01), None
patent: WO 2004/009582 (2004-01-01), None
Adha, et al., “Synthesis of Complex Ethynyladenosines Using Organic Triflic Enolates in Palladium-Catalyzed Reactins: Potential Agonists for the Adenisone A2Receptor” Tetrahedron, vol. 53, No. 20; pp. 2747-6754, (1997).
Baichwal & Baeuerle, “Apoptosis: Activate NF-KB or die?” Current Biology, 7:R94-R96 (1997).
Comins, D. L. et al., “Lithiation of Heterocycles Directed by α-Amino Alkoxides” J. Org Chem. 52; pp. 104-109 (1987).
Eloy, F. and Deryckere, A., “Thienopyridines” Bulletin des Societes Chimiquest Belges; pp. 301-311 (1970) (English Abstract Provided at C05).
English Abstract of C04. Eloy, F., and Deryckere, A. “Thienopyridines” Bulletin des Societes chimiquest Belges 79, 301-311 (1970).
Gjoes et al., “Some Substitution Reactions of 2-Phenylthiophene” Acta Chemica Scandinavica, vol. 26, No. 5, 1751-2162 (1972).
Hehner, S.P. et al., “The anti-inflammatory sesquiterprene lactone parthenolide inhibits NV-kB by targeting the 1kB kinase complex”, J. Immunol., vol. 163; pp. 5617-5623 (1999).
Junek, H., et al., “Synthesen von Alkyl-bzw. Cycloalkylpyridinen and Naphthyridinen,”Monatshefte fuer Chemie.;vol. 108, No. 3; pp. 689-702 (1977) (English Abstract Provided at C9).
English Abstract of C08. Junek, H., et al., “Report on the chemistry of enaminoketones, part 13, Syntheses of alkyl-cycloalkylpyridines, and naphthyridines”, Montashefte fuer chemie, vol. 108, No. 3, pp. 689-702 (1977).
Karin, J., “The beginning of the End: 1kB Kinase (1kk) and NF-kB Activation”, The Journal of Biological Chemistry, vol. 274, No. 39, pp. 27339-27342, Issue of Sep. 24, 1999.
Koitz, G. et al., “Condensation products of dimeric malononitrile derivatives with 2,4-diketones and their application for the synthesis of substituted 1,6-naphtyridines”, Heterocycles, vol. 20, No. 12; pp. 2405-2409 (1983).
Malinin, N. et al., “MAP3K-related kinase involved in NF-kB induction by TNF, CD95 and IL-1”, Nature, vol. 385, pp. 540-544 (1997).
Mercurio, F., et al, “IKK-1 And IKK-2: Cytokine-Activated IkB Kinases Essential for NF-kB Activation”, Science, vol. 278; pp. 1054-1068 (1997).
Poirier, Y. et al, “Composes sulfures heterocycliques. Xx(*).—Sulfration d'alcoylidene cyclopentanones” Bulletin de la Societe Chimique de France; pp. 1054-1068 (1996) (English Abstract Provided at C15).
English Abstract of C14. Poirier, Y. et al, “Heterocyclic sulfur compounds. xx. Sulfuration of alklidenecyclopentanones” Bulletin de la Societe Chimique de France; pp. 1052-1068 (1966).
Silberg, A., et al., “Beitrage zum Studium der Thiazole, VIII” Chem. Ber , 97(6); pp. 1684-1687, (1964) (English Abstract Provided at C17).
English Abstract of C16. Silberg, A., et al., “Thiazoles. VIII. Phenylthiazolecarboxaldehydes” Chem. Ber , 97(6); pp. 1684-1687, (1964).
Silverman, J. et al., “3840 In Vitro and in vivo activity of SPC-595, a novel cell cycle inhibitory cytotoxic in murine syngeneic and human xenograft tumor models” Presentation at the 95thAmerican Association for Cancer Research, Mar. 27-31, 2004.
Skorcz, J. A., Suh, J.T.; Germershausen, R. L. J. Heterocyclic, vol. 10; pp. 249-253 (1973).
Verma, et al., Genes & Development, vol. 9, No. 22; pp. 2723-2872 (1995).
Woronicz, J.D., et al., “Iκβ: NF-κB Activation and complex Formation with IκB Kinase-α and NIK” Science, vol. 278; Oct. 31, 1997.
Zhang, Y., Homfeldt, A.-B; Gronowitz, S.; Stalhandske C. “Pyridine-Substituted Hydroxythiophenes. III. Dimerization of 3-(2-Pyridyl)thiophen-2(5H)-one from Demethylation Reaction of 2-Methoxy-3-(2-pyridyl)thiophene. X-Ray Structure Determination of (±)-(3R*, 4S*)-3-(2-Pyridyl)-4-[2-oxo-3(1,2-dihydropyridin-2-ylidene)-2,3-dihydro-thiophen-5-yl]-4,5-dihydrothiophen-2(3H)-one” Acta Chemica Scand. vol. 48; pp. 843-849 (1994).
Burkitt Simon A.
Cardozo Mario G.
Cushing Timothy D.
DeGraffenreid Michael R.
Farthing Christopher N.
Amgen Inc.
Anderson Rebecca
Jones Day
LandOfFree
Antiinflammation agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiinflammation agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiinflammation agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752041